Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Gantenerumab HCLF vs LyoF in Healthy Volunteers
NCT02133937Phase 1Completed
- Sponsor
- Roche
- Start
- Apr 2014
- Primary completion
- Sep 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of gantenerumab in Alzheimer's disease (AD) (2 arms), sponsored by Roche. Primary endpoint: Plasma concentration of gantenerumab at 13 weeks. Started Apr 2014; status: completed.
02
Drugs
gantenerumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02133937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02133937.